China-Developed Drug Out-Licensing Deal Reaches Over 15.5 Billion Dollars Nominal Value, Second Largest on Record

A license-out deal for a China-developed innovative drug has a nominal total value exceeding 15.5 billion US dollars, ranking second in the history of such out-licensing deals. The consideration includes a 400 million dollar upfront payment, a 110 million dollar one-year anniversary payment, potential milestones exceeding 15 billion dollars, and tiered royalties.